Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

@article{Sanda1999RecombinantV,
  title={Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.},
  author={Martin G. Sanda and David C. Smith and Linda Charles and Chung-yeon Hwang and Kenneth J. Pienta and Jeffrey Schlom and Dejan Milenic and Dennis Panicali and James E. Montie},
  journal={Urology},
  year={1999},
  volume={53 2},
  pages={
          260-6
        }
}
OBJECTIVES Prostate cancer recurrence, evidenced by rising prostate-specific antigen (PSA) levels after radical prostatectomy, is an increasingly prevalent clinical problem in need of new treatment options. Preclinical studies have suggested that for tumors in general, settings of minimal cancer volume may be uniquely suitable for recombinant vaccine therapy targeting tumor-associated antigens. A clinical study was undertaken to evaluate the safety and biologic effects of vaccinia-PSA (PROSTVAC… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 83 CITATIONS, ESTIMATED 48% COVERAGE

From Bench to Bedside: Immunotherapy for Prostate Cancer

  • BioMed research international
  • 2014
VIEW 16 EXCERPTS
HIGHLY INFLUENCED

Androgen deprivation and immunotherapy for the treatment of prostate cancer.

  • Endocrine-related cancer
  • 2017
VIEW 2 EXCERPTS
CITES METHODS & BACKGROUND

Current status of clinical trials assessing oncolytic virus therapy for urological cancers.

  • International journal of urology : official journal of the Japanese Urological Association
  • 2017

FILTER CITATIONS BY YEAR

1999
2018

CITATION STATISTICS

  • 2 Highly Influenced Citations